Day: October 4, 2021

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation...

ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia

YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the...

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

-Phase 1b study will investigate the efficacy of REVTx-99 on nasal symptoms elicited by nasal allergen challenge- -Top-line data anticipated...

error: Content is protected !!